Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/08/23
Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings SeasonZacks Investment Research • 03/02/23
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 03/01/23
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023Business Wire • 03/01/23
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic CholestasisBusiness Wire • 02/14/23
Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma ConferenceBusiness Wire • 02/09/23
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate UpdatesBusiness Wire • 01/09/23
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023Business Wire • 01/03/23
Mirum Pharmaceuticals' LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderBusiness Wire • 12/13/22
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/22
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/09/22
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLDBusiness Wire • 11/07/22
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 11/02/22
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022Business Wire • 11/01/22
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver DiseaseBusiness Wire • 10/27/22
Positive Topline Data Announced from Mirum's LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)Business Wire • 10/24/22
Mirum Pharmaceuticals' LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of PediatricsBusiness Wire • 10/18/22
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and OlderBusiness Wire • 10/14/22
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual MeetingBusiness Wire • 10/12/22
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual MeetingBusiness Wire • 10/05/22